Thinly traded Cue Biopharma (NASDAQ:
CUE) is up
3% premarket on light volume on the heels of
updated data
from a Phase 1 clinical trial evaluating lead candidate CUE-101 for the
second-line treatment of patients with HPV-positive
recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).
As of June 15, 13 patients have been enrolled,
most receiving multiple cycles of therapy. Six remain on study for the
ongoing data presentation.
Drug exposure in line with preclinical projections
and is dose-proportional. Comparable exposures observed upon repeated
administration.
Pharmacodynamic data showed selective expansion of
targeted T cells in the peripheral blood of several participants in
cohorts 2 and 3.
Preliminary radiographic evidence showed CUE-101 to be clinically active.
The company says it appears to have an “attractive” therapeutic window.
On the safety front, most treatment-related
adverse events have been mild or moderate with no discontinuations.
There was one severe adverse event (anemia and fatigue) that was
possibly treatment-related. The patient had an underlying condition and
remains on study. The anemia was resolved following a blood transfusion.
CUE-101,
a member of the CUE-100 series, is a fusion protein designed to
selectively activate tumor-specific T cells to fight HPV-driven cancers.
https://seekingalpha.com/news/3582965-cue-biopharmas-lead-drug-shows-encouraging-action-in-cancer-study
